Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells |
| |
Authors: | Wei Qiang Costanzi Stefano Liu Qiu-Zhen Gao Zhan-Guo Jacobson Kenneth A |
| |
Affiliation: | aMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0810, USA;bGuangdong Institute of Kidney Diseases, Nan Fang Hospital, Southern Medical University, Guangzhou 510515, PR China;cLaboratory of Biological Modeling, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0810, USA;dInfectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892-0810, USA |
| |
Abstract: | ![]() G protein-coupled receptors, the largest cell surface receptor family, have emerged as critical players in cell death and survival. High gene expression level of the Gq-coupled P2Y1 nucleotide receptor in PC-3 prostate cancer cells was demonstrated using real-time quantitative PCR and confirmed by Western blotting and confocal laser scanning microscopy. A selective P2Y1 receptor agonist, the ADP analogue MRS2365, concentration-dependently induced intracellular calcium mobilization (EC50 5.28 nM), which was diminished by P2Y1 receptor-selective antagonist MRS2500. P2Y1 receptor activation by MRS2365 induced apoptosis in assays of Caspase-3, LDH release, and annexin-V staining. The pro-apoptotic effect of MRS2365 was blocked by MRS2500, P2Y1 siRNA, and an inhibitor of the MAP kinase pathway PD98059. MRS2365 significantly inhibited the proliferation of PC-3 cells, examined using a MTT assay. Thus, activation of the P2Y1 receptor induced cell death and inhibited growth of human prostatic carcinoma PC-3 cells. Activation of the P2Y1 receptor should be a novel and promising therapeutic strategy for prostate cancer. |
| |
Keywords: | Abbreviations: 7-AAD, 7-aminoactinomycin D CHX, cycloheximide ERK, extracellular receptor-activated kinase FBS, fetal bovine serum FITC, fluorescein isothiocyanate GAPDH, glyceraldehyde-3-phosphate dehydrogenase LDH, lactate dehydrogenase MAP kinase, mitogen-activated protein kinase MRS2179, N6-methyl-2&prime -deoxyadenosine-3&prime ,5&prime -bisphosphate MRS2365, (N)-methanocarba-2&prime -deoxy-2-methylthio-adenosine-5&prime -diphosphate MRS2500, 2-iodo-N6-methyl-(N)-methanocarba-2&prime -deoxyadenosine-3&prime ,5&prime -bisphosphate 2-MeSADP, 2-methylthioadenosine 5&prime -diphosphate MTT, 3-(4,5-dimethylethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide PBS, phosphate-buffered saline TNF-α, tumor necrosis factor-alpha |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|